GSK, the British pharmaceutical giant, has significantly raised its long-term sales outlook for the period between 2026 and 2031. The company anticipates that the launch of new drugs and vaccines will propel its annual sales to reach £38 billion by the beginning of the next decade. One of the key factors contributing to this positive projection is the hugely successful release … [Read more...] about GSK Raises Long-Term Sales Outlook
GSK
GSK Settlement in Zantac Cancer Case
GSK, a British pharmaceutical company, has announced a confidential settlement in the David Browne case filed in California state court. This case pertains to allegations that the heartburn medicine Zantac causes cancer. While no specific details of the settlement were provided, GSK confirmed that the trial set for February 20 will now be dismissed. In a statement, GSK … [Read more...] about GSK Settlement in Zantac Cancer Case
GSK Expands Respiratory Pipeline with Acquisition of Aiolos Bio
GSK, a prominent British pharmaceutical company, has announced its acquisition of biopharmaceutical company Aiolos Bio for a staggering $1.4 billion. This strategic move allows GSK to bolster its respiratory pipeline and aligns with the recent trend of pharmaceutical giants acquiring rapidly growing biotechs to strengthen their portfolios. Aiolos Bio, headquartered in both San … [Read more...] about GSK Expands Respiratory Pipeline with Acquisition of Aiolos Bio
